the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Category | Publishers | Custom Research | E-mail Alert | About Us | Contact Us | Site Map |
 
RSS Feed
Pharmaceutical
Drug Discovery
Drug Delivery System
Veterinary Medicine
Bone Disease Treatment
Obesity Treatment
Generic Drugs
OTC Drug
Prescription Drugs
Vaccines
Regulation
Cancer
Diabetes
Infection Disease
Mental Disease
Pharmaceutical Companies
Neurodegenerative Disease

* View All Categories
View Conferences
Japanese Korean Chinese
Home > Category > Pharmaceutical >

Market Research Report

Parkinson's Disease Market analysis and forecasts, 2008-2012, 2017 & 2022

Published by Visiongain Contact us : +1-860-674-8796
Published 2008/01 Content info 150 pages
Product code KT63222
Price From  US $ 2502 Order/Price list
US $ 2502 PDF by E-mail (Single User License)
US $ 5006 PDF by E-mail (Department License)
US $ 8343 PDF by E-mail (Site License)
US $ 11687 PDF by E-mail (Global Site License)
How to Order?
Delivery Time
PDF by E-Mail
Approx. 1-2 business days
Hard Copy/CD-ROM
Approx. 3-4 business days
If you need expedited delivery, please call us.
Description TOC

Table of Contents

Chapter 1 Executive Summary

Chapter 2 Introduction To Parkinson' s Disease (PD)

  • 2.1 Parkinson' s Disease Overview
  • 2.2 Pathophysiology Of PD
  • 2.3 Types Of Age-Related Parkinson' s Disease
  • 2.4 Parkinson' s Disease Rating Scale
  • 2.5 Etiology of Parkinson' s Disease
  • 2.6 What are the Risk Factors?
    • 2.6.1 Age
    • 2.6.2 A possible Genetic Basis To PD
    • 2.6.3 Men Are More Likely To Develop PD
    • 2.6.4 Pesticides And Herbicides Influence PD Development
    • 2.6.5 Reduced Oestrogen Levels Increase The Risk Of PD
    • 2.6.6 Reduced Folate Levels Associated With PD
    • 2.6.7 Anti-Oxidants
  • 2.7 Initial Presentation Of PD
    • 2.7.1 Tremors
    • 2.7.2 Rigidity
    • 2.7.3 Akinesia
    • 2.7.4 Postural Instability
    • 2.7.5 Comobidities Of PD
      • 2.7.5.1 Sleep Disturbances In PD
      • 2.7.5.2 Dementia
      • 2.7.5.3 Depression
      • 2.7.5.4 Sexual Dysfunction
      • 2.7.5.5 Emotional Disturbances
      • 2.7.5.6 Weight Loss
      • 2.7.5.7 Shortness Of Breath
      • 2.7.5.8 Visual Impairment
      • 2.7.5.9 Potential Risk of Falling
      • 2.7.5.10 Other Autonomic Nervous System Disturbances
  • 2.8 Symptoms Of PD
  • 2.9 Diagnosis Of PD
    • 2.9.1 Proven Diagnostic Criteria For PD
      • 2.9.1.1 Neurological Evaluation Of PD
      • 2.9.1.2 Laboratory Evaluation Of PD
      • 2.9.1.3 Imaging Studies For PD
  • 2.10 Prognosis Of PD- Hoenn And Yahr Scale
  • 2.11 Demographics Of PD (Incidence And Prevalence)
  • 2.12 Financial Burden Of PD

Chapter 3 Pharmacotherapy for PD

  • 3.1 Current Pharmaceutical Therapies Of PD Available In The PD Market
  • 3.2 Classes Of Drugs Available In The PD Market
  • 3.3 Dopamine Precursors As The Standard Treatments For PD
    • 3.3.1 Side-Effects Of Levodopa
  • 3.4 Dopamine Agonists As Treatments For PD
    • 3.4.1 Requip (Ropinirole)
    • 3.4.2 Sifrol/Mirapexin (Pramipexole) a Dopamine D2 Agonist Is The Leading PD Drug
    • 3.4.3 Parlodel (Bromocriptine)
    • 3.4.4 Dopergine (Lisuride) Is Superior To Parlodel
    • 3.4.5 Permax (Pergolide)
    • 3.4.6 Side-Effects Of Dopamine Agonist
  • 3.5 Monoamine Oxidase B Inhibitors ((MAO-B)
    • 3.5.1 Deprenyl (Selegeline)
      • 3.5.1.1 Side Effects Of Selegeline
  • 3.5.2 Rasagiline (Azilect)
  • 3.6 COMT (Catechol-O-Methyl Transferase) Inhibitors
    • 3.6.1 Tasmar (Tolcapone) As An Adjunct Therapy
    • 3.6.2 Comtess (Entacapone) To Aid PD Treatment
  • 3.7 Dopamine And COMT Combined
    • 3.7.1 Stalevo The Combination Therapy
  • 3.8 Anticholinergics (Antimuscarinic drugs)
    • 3.8.1 Congentin (Benzatropine Mesilate)
    • 3.8.2 Artane (Trihexyphenidyl) To Control Common Symptoms
  • 3.9 Antihistamines And Antidepressants Can Aid PD Symptoms?
  • 3.10 Apomorphine as Additional Relief for PD Sufferers
  • 3.11 N-Methyl-D-Asparate Receptor Antagonists (NMDA)
  • 3.12 Antiviral Drugs -Symmetrel (Amantadine)
  • 3.13 Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Receptor Antagonist
    • 3.13.1 Talampanel
  • 3.14 Parkinson' s Patch Approved In Europe For All Stages Of Parkinson' s Disease
  • 3.15 Novartis' Exelon Alzheimer' s Drug For PD
  • 3.16 Surgical Therapy Is Not a Popular Treatment Of PD
    • 3.16.1 Thalamotomy Only Used To Reduce Tremors
    • 3.16.2 Pallidotomy Is Becoming More Popular As A Treatment For PD
  • 3.17 Medtronic Activa Therapy Survey

Chapter 4 Parkinson' s Disease World Market Analysis

  • 4.1 The World Market For PD Drugs Will Show Significant Growth To 2012
  • 4.2 PD Sales Revenues
  • 4.3 Sifrol /Mirapex (pramipexole) The Leading Dopamine Agonists for PD
  • 4.4 Successful 50-month Study Positions Mirapex As First-Line Drug For PD In EU
  • 4.5 Sifrol And Other Newer Products Reclaim Market Share From Anticholinergics And L-Dopa Generics
  • 4.6 Sifrol Gradually Losing Market Share To GSK' s Requip
  • 4.7 FDA Accepts GSK/SkyePharma Once-Daily Requip (Ropinirole HCl) XL 24-Hour Extended-Release Tablets
  • 4.8 key Findings Supporting Success of Requip
  • 4.9 Requip Experiences Continuous Sales Growth
  • 4.10 Pfizer' s Cabaser/Dostinex (Cabergoline) Outperformed By Sifrol
  • 4.11 Dopaminergic Market
    • 4.11.1 Sinemet (Co-Careldopa)
    • 4.11.2 Madopar (Co-benelopa)
    • 4.11.3 Carbidopa and Benserazide
    • 4.11.4 Monoamine Oxidase B Inhibitor-Azilect (Rasagiline)
  • 4.12 The TEMPO Study-Rasagiline In Early PD
    • 4.12.1 The TEMPO Extended Study
    • 4.12.2 The PRESTO And LARGO Studies - Rasagiline In Moderate-To-Advanced PD
  • 4.13 Azilect With Potential To See Significant Revenue Growth
  • 4.14 Comtan (Entacapone) Leading COMT Inhibitors Captures Tasmar' s Market Share
  • 4.15 Orions' Comtess
  • 4.16 Stalevo Combination Therapy Drives Sales Growth

Chapter 5 Major Market Analysis

  • 5.1 Major Markets Experience Year-on-Year Revenue Expansions
  • 5.2 The US Is the Largest PD Market
  • 5.3 Japan Experience Sales Decline In 2006
  • 5.4 EU PD Profit Margins Exceed The US
  • 5.5 Germany Leads The EU Markets
  • 5.6 The UK Market Experienced The Smallest Revenue Growth In 2006
  • 5.7 France PD Pharmaceutical Revenue Growth Expands
  • 5.8 Rising Sales Growth In Italian PD Market
  • 5.9 Spain Experiences Highest Growth in EU PD Market in 2006

Chapter 6 Experts' Views on Main Issues in the Treatment of PD

  • 6.1 The Most Important Unmet Medical Needs In The Treatment of Parkinson' s Disease (PD)
  • 6.2 Which Drugs Will Be Central Part Of Treatment For Between Now And 2020?
  • 6.3 Do You Think That The Present Drugs Are Cost-effective?
  • 6.4 Will Public And Private Healthcare In EU And Drugs For The Treatment Of PD?
  • 6.5 What Is The Current Market Valuation For PD Drugs?
  • 6.6 Do You Think Compounds That Can Deliver Neuroprotection Will Change The Dynamics Of The PD Market?
  • 6.7 Are There Any Products In The Pipeline That Will Change The Market - Which Ones And Why Do You Think So?
  • 6.8 How Quickly Will This Market Grow Once A Wider Range Of Drugs is Introduced?
  • 6.9 Which Companies Do You Think Will Become Involved In This Market, And Make A Significant Impact?
  • 6.10 Do You Think Through Gene Therapy Has A Place In The Treatment Of PD?
  • 6.11 Concluding Thoughts

Chapter 7 Pipeline Developments In Parkinson' s Treatment

  • 7.1 The Scope Of PD Pipeline
  • 7.2 Emerging Therapies For Parkinson' s Disease Small Molecule Drugs
    • 7.2.1 ALS Drug, Rilutek (Riluzole), To Help PD Patients
    • 7.2.2 HD Treatment, Remacemide (Remacemide hydrochloride), For PD
  • 7.3 Other New Drugs in Development
    • 7.3.1 Wyeth And Curis Hedgehog Signalling Pathway Research Potential For Neurodegenerative Diseases
    • 7.3.2 The Process Of Apoptosis In Parkinson' s Disease
    • 7.3.3 Pig Neuron Implantations As New Treatments For PD
    • 7.3.4 A Nerve Growth Promoter May Have a Role In PD Treatment
    • 7.3.5 The Implantation Of Dopamine Producing Cells As A Novel Therapy In PD
    • 7.3.6 GDNF Gene Therapy As A New Treatment Therapy
    • 7.3.7 Biogen Idec And Vernalis Phase II BIIB014 oral Compound
    • 7.3.8 Subcutaneous Drug Delivery System Underway For Treatment Of PD
    • 7.3.9 Neuroprotective Agent PD 02 Slows PD Progression In Phase II Trials
    • 7.3.10 Merck Serono And Newron' s Safinamide Effective In Early And Late-Stage Parkinson' s Disease
    • 7.3.11 Signalling Ret-Receptors Protect The Live Of Nerve Cells In The Aging Brain
    • 7.3.12 Kyowa Hakko Istradefylline (KW- 6002)
    • 7.3.13 Neurologix Completes Phase I GAD Gene Therapy Trial For Parkinson' s Disease.
    • 7.3.14 Ceregene In A Phase II Neurturin Gene Therapy Study
    • 7.3.15 Arundic Acid An Astrocyte Modulating Agent For PD
    • 7.3.16 Antioxidative Properties Of Vitamin E, C And Health Food
    • 7.3.17 Coenzyme Q10 as a potential antioxidant
    • 7.3.18 Alseres Pharmaceuticals Altropane PD Diagnostic Tool For PD

Chapter 8 Global AD Pharmaceutical & Healthcare Industry SWOT Analysis

  • 8.1 SWOT Analysis Of The Parkinson' s Disease Market
  • 8.2 Unmet Medical Needs For PD
  • 8.3 Patient Potential To Drive Anti-PD Market
  • 8.4 Major Restraints Of The PD Market
  • 8.5 Patient Focus Or Drug Focus?
  • 8.6 Patients To Bear Cost Of Increasing Regulatory Requirements
  • 8.7 More Focus On Patients During Clinical Studies
  • 8.8 Generic Competition
  • 8.9 Technology Transfer in PD
  • 8.10 Leading Drugs Still Carry Motor Complications
  • 8.11 Teva And Lundbeck' s Azilect To Lead The Way In Future Therapy
  • 8.12 Biomarker and Pharmacogenetics
  • 8.13 Potential Application Of Biomarkers And Pharmacogenetic (Pharmacogenomics)
  • 8.14 High Return-On-Investment In PD Market
  • 8.15 Cost-effective Analysis Will Be A Potential Threat For Reimbursement
    • 8.15.1 Controversy Over NICE' s Decisions
    • 8.15.2 Will CEA Be Disincentive To R&D?
  • 8.16 Reformulation Of Drugs To Drive Revenue Growth
  • 8.17 Schwarz Pharma PD Transdermal Patch To Reduce Polypharmacy
  • 8.18 Impact Of Parkinson' s Disease Will Continue To Stretch Healthcare Budget Until when Pharmacological Agents Are Able To Address Unmet Needs
  • 8.19 Pallidotomy Is Becoming More Popular As A Treatment For PD
  • 8.20 Change Of Patients And Physician Attitude Will Be Essential For Growth Of PD Market

Chapter 9 Conclusion

  • 9.1 Global Market Will Experience Sustained Revenues Markets Set To Experience Rise In Revenue Growth
    • 9.2.1 The US PD Revenue Growth Champions Other Markets
    • 9.2.2 Japan To Experience Slow Revenue Growth
    • 9.2.3 EU PD Profit Margins Exceed US
    • 9.2.4 Germany Leads The EU PD Markets
    • 9.2.5 The UK Market Experienced The Smallest PD Revenue Growth in 2006
    • 9.2.6 France PD Pharmaceutical Revenue Growth Expands
    • 9.2.7 Rising Sales Growth In Italian PD Market
    • 9.2.8 Spain Experiences Highest Growth In EU PD Market
  • 9.3 Rising Patient Potential and Improved Therapeutics Will Drive PD Global Revenue Growth
  • 9.4 Promising R&D Pipeline

List of Tables

  • Table 1.1 PD Global and Regional Revenue Forecast ($m) 2007-2012,2017 & 2022
  • Table 1.2 Patent Expiration on Leading anti-Parkinson' s Drugs
  • Table 1.3 Prevalence of Parkinson' s Disease Accross The Seven Major Markets (2006)
  • Table 2.1 Factor that may influence Parkinson' s Disease
  • Table 2.2 Prognosis of PD by Hoehn and Yahr scale
  • Table 4.1 Global PD Market Forecast ($m),2007-2012,2017 & 2022
  • Table 4.2 The Global Parkinson' s disease Market,2004-2006
  • Table 4.3 Sifrol Global Sale Forecast ($m),2007,2017 & 2022
  • Table 4.4 Requip Global Sale Forecast ($m),2007,2017 & 2022
  • Table 4.5 Cabaser Global Sale Forecast ($m),2007,2017 & 2022
  • Table 4.6 Sinemet Global Sale Forecast ($m),2007,2017 & 2022
  • Table 4.7 Madopar Global Sale Forecast ($m),2007,2017 & 2022
  • Table 4.8 Azilect Global Sale Forecast ($m),2007,2017 & 2022
  • Table 4.9 Comtan Global Sale Forecast ($m),2007,2017 & 2022
  • Table 4.10 Stalevo Global Sale Forecast ($m),2007,2017 & 2022
  • Table 5.1 Sales ($m) of Leading PD drugs in the US Market,2004-2006
  • Table 5.2 US PD Sales Forecast ($m),2007,2017 & 2022
  • Table 5.3 Sales ($m) of Leading PD drugs in the Japanese Market,2004-2006
  • Table 5.4 Japan PD Sales Forecast ($m),2007,2017 & 2022
  • Table 5.5 Regional Annual PD Revenues ($m),2005-2006
  • Table 5.6 Regional PD Revenues ($m),2005-2006
  • Table 5.7 Sales ($m) of Leading PD drugs in the Japanese Market,2004-2006
  • Table 5.8 Germany PD Sales Forecast ($m),2007,2017 & 2022
  • Table 5.9 Sales ($m) of Leading PD drugs in the UK Market,2004-2006
  • Table 5.10 UK PD Sales Forecast ($m),2007,2017 & 2022
  • Table 5.11 Sales ($m) of Leading PD Drugs in France,2005-2006
  • Table 5.12 France PD Sales Forecast ($m),2007,2017 & 2022
  • Table 5.13 Sales ($m) of Leading PD Drugs in Italy,2005-2006
  • Table 5.14 Italy PD Sales Forecast ($m),2007,2017 & 2022
  • Table 5.15 Sales ($m) of Leading PD Drugs in Italy,2005-2006
  • Table 5.16 Spain PD Sales Forecast ($m),2007,2017 & 2022
  • Table 7.1 Parkinson' s disease Pipeline,2006
  • Table 8.1 SWOT Analysis of the Parkinson' s disease Market
  • Table 8.2 Economic Evaluation in EU Major Markets, 2006
  • Table 8.3 Economic Evaluation in EU Major Markets 2006

List of Charts

  • Chart 1.1 PD Global Revenue Forecast ($m) 2007-2012,2017 & 2022
  • Chart 1.2 PD Regional Revenue Forecast ($m) 2007-2012,2017 & 2022
  • Chart 1.3 Deomographics of Parkinson' s Disease Across Major Markets,2006
  • Chart 4.1 The Global Parkinson' s disease Market,2004-2006
  • Chart 4.2 The Global Parkinson' s disease Drugs Market Share, 2006
  • Chart 4.3 Sifrol Global Sales ($m) 2003-2006
  • Chart 4.4 Sifrol Global Sale Forecast ($m),2007,2017 & 2022
  • Chart 4.5 Requip Global Sales ($m) 2003-2006
  • Chart 4.6 Requip Global Sale Forecast ($m),2007,2017 & 2022
  • Chart 4.7 Cabaser Global Sales ($m) 2003-2006
  • Chart 4.8 Cabaser Global Sale Forecast ($m),2007,2017 & 2022
  • Chart 4.9 Sinemet Global Sales ($m),2003-2006
  • Chart 4.10 Sinemet Global Sale Forecast ($m),2007,2017 & 2022
  • Chart 4.11 Madopar Global Sales ($m), 2003-2006
  • Chart 4.12 Madopar Global Sale Forecast ($m),2007,2017 & 2022
  • Chart. 4.13 Azilect Global Sale Forecast ($m),2007,2017 & 2022
  • Chart 4.14 Comtan Global Sales ($m),2003-2006
  • Chart 4.15 Comtan Global Sale Forecast ($m),2007,2017 & 2022
  • Chart 4.16 Comtess Global Sales ($m),2003-2006
  • Chart 4.17 Stalevo Global Sales ($m),2003-2006
  • Chart 4.18 Stalevo Global Sale Forecast ($m),2007,2017 & 2022
  • Chart 4.19 Global PD Market Forecast ($m),2007-2012,2017 & 2022
  • Chart 5.1 Market Share of Leading PD drugs in the US Market,2004-2006
  • Chart 5.2 US PD Sales Forecast ($m),2007,2017 & 2022
  • Chart 5.3 Market Share of Leading PD drugs in Japan,2006
  • Chart 5.4 Japan PD Sales Forecast ($m),2007,2017 & 2022
  • Chart 5.5 Market Share of PD Revenues ($m), 2006
  • Chart 5.6 Market Share of Major EU PD markets
  • Chart 5.7 Market Share of Leading PD drugs in Germany,2006
  • Chart 5.8 Germany PD Sales Forecast ($m),2007,2017 & 2022
  • Chart 5.9 Market Share of leading PD drugs in the UK,2006
  • Chart 5.10 UK PD Sales Forecast ($m),2007,2017 & 2022
  • Chart 5.11 Market Share of PD Drugs in France 2006
  • Chart 5.12 France PD Sales Forecast ($m),2007,2017 & 2022
  • Chart 5.13 Market Share of PD Drugs in Italy 2006
  • Chart 5.14 Italy PD Sales Forecast ($m),2007,2017 & 2022
  • Chart 5.15 Market Share of PD Drugs in Spain, 2006
  • Chart 5.16 Spain, PD Sales Forecast ($m),2007,2017 & 2022
  • Chart 8.1 Unmet need at Early Stages of Parkinson' s disease
  • Chart 8.2 Unmet need at Late Stages of Parkinson' s disease
  • Chart 8.3 Spectrum of Present Unmet needs in PD management
  • Chart 8.4 Significant Factors to Driveb Revenue Growth of PD Market
  • Chart 8.5 Restraining factors to Potential Revenue growth of PD Market

Companies and Organisations

  • Abbott
  • Aeolus
  • Alliance
  • Alseres
  • Amarin
  • Amgen
  • Antipodean
  • AstraZeneca
  • Avicena
  • Avigen
  • Bar
  • BarIlan University
  • Biogen Idec
  • Biomas
  • Boehringer Ingelheim
  • BristolMyersSquib
  • Britannia
  • Cell Genesys
  • Ceregene
  • Dainippon Sumitomo
  • Diamyd Medical
  • Eisai
  • Elan
  • Eli Lily
  • Faust Pharmaceutical
  • Forest
  • Fujomo
  • Genzyme
  • Georgetown University
  • Guilford
  • Juvantia
  • Kyowa Hakko
  • Lederle
  • Lunbeck
  • Max Planck Institute of Neurobiology
  • Medtronic
  • Meiji Seika
  • Merck KGaA
  • Merck Serono
  • Mertz
  • Merz
  • Mylan
  • National Patent Development
  • Neuren
  • Neurobiotics
  • NeuroCell
  • Neurologix
  • Newron
  • Novartis
  • ONO
  • Orion
  • Pfizer
  • Pharmaplaz
  • Phytrix
  • Prestwick
  • Roche
  • Samaritan
  • Sanofi-Aventis
  • Santhera
  • Schering-Plough
  • Schwarz Pharma
  • Scientific Testing
  • Siegfried
  • SkyePharma
  • Solvay
  • Syngis
  • The National Institute of Neurological Disorder and Stokes (NINDS
  • The New England Journal of Medicine
  • Valeant
  • Vernalis
  • Wyeth
Related Report
Alzheimer disease - new drugs, markets and companies Drug Delivery in Central Nervous System Diseases - technologies, markets and companies Neuroprotection - Drugs, Markets and Companies Commercial Insight: Anticonvulsants - Non-epilepsy label expansions provide blockbuster potential Commercial Insight: Parkinson's Disease - Japan and Europe to drive total market growth
Back to Top
Please inform me when related publications are released
InfoWatch

| FAQ | About The Infoshop | Policies | Site Map |
US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2009, the-infoshop.com by Global Information, Inc. All rights reserved.